Boehringer takes nintedanib to EMA; California governor vetoes biosimilars bill;

@FierceBiotech: Analysts offer giddy forecasts for booming cancer immunotherapy pipeline. More | Follow @FierceBiotech

@JohnCFierce: PhIII blunders that have helped define companies, for better or worse. The top Phase III R&D setbacks of 2013 | Follow @JohnCFierce

@DamianFierce: If Myriad was a big dog in a small park in its fight with Ambry and Gene by Gene, Quest is a dog colossus. | Follow @DamianFierce

> Boehringer Ingelheim has filed for EMA approval for nintedanib, a non-small cell lung cancer treatment. Article

> California Gov. Jerry Brown has vetoed a bill that would have allowed pharmacists to automatically replace biologics with biosimilars once the FDA declared the two interchangeable. Story

> Cel-Sci ($CVM) has signed a codevelopment and profit-sharing deal with CRO Ergomed, covering its cancer drug Multikine in cervical dysplasia patients with HIV and HPV. More

Medical Device News

@FierceMedDev: Natera expands prenatal test amid global push. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Who are this year's FMD Fierce 15 winners? Find out here | Follow @MarkHFierce

@MichaelGFierce: Critical Diagnostics launches point-of-care cardiac disease test. Item | Follow @MichaelGFierce

> J&J's med tech biz falters amid weak sales, M&A rumors. Story

> Senate debt, government funding compromise avoids addressing device tax repeal. Report

Pharma News

@FiercePharma: Biggest new news Monday: Irate Teva reps vow to strike against Israeli job cuts. Story | Follow @FiercePharma

@CarlyHFierce: Sanofi nabs OTC nod for Nasacort amid consumer healthcare push. ICYMI yesterday | Follow @CarlyHFierce

> J&J hikes earnings forecast on pharma's superhero sales flight. More

> Savient gives up the ghost; buyer aims to snap up Krystexxa. Article

Biotech Research News

@EmilyMFierce: Parkinson's may take two forms, one more toxic than the other. More | Follow @EmilyMFierce

> Vegetable-based compound protects against side effects of radiation therapy. Story

> Evotec gets $5.4M from Boehringer Ingelheim in cancer research pact. Report

> Compound halts neurodegeneration in mice. More

> Gene therapy plus stem cells quickens wound healing. Article

> Boston University, MRC Technology developing anti-inflammatory antibody. Item

Pharma Manufacturing News

@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article | Follow @EricPFierce

> U.S. awards special status to fired Novartis workers. Report

> Israeli unions threaten strikes over Teva job cuts. Item

> FDA closes out inspection on Ranbaxy New Jersey plant. More

> SAFC adds biologics capabilities at 2 plants. News

> Roche expanding biologics production in 3 countries. Story

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.